Authors: MARINO MR LANGENBACHER KM FORD NE BEIERLE F RAYMOND RH SHAMBLEN EC LASSETER KC

Citation: Mr. Marino et al., EFFECT OF HYDROCHLOROTHIAZIDE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ANGIOTENSIN-II BLOCKER IRBESARTAN, Clinical drug investigation, 14(5), 1997, pp. 383-391

Authors: MARINO MR LANGENBACHER KM FORD NF BEIERLE F SHAMBLEN EC LASSETER KC

Citation: Mr. Marino et al., EFFECT OF HYDROCHLOROTHIAZIDE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF IRBESARTAN, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 52-52

Authors: SCHWARTZ JI VANHECKEN A DESCHEPPER PJ DELEPELEIRE I LASSETER KC SHAMBLEN EC WINCHELL GA CONSTANZER ML CHAVEZ CM WANG DZ EBEL DL JUSTICE SJ GERTZ BJ

Citation: Ji. Schwartz et al., EFFECT OF MK-386, A NOVEL INHIBITOR OF TYPE-1 5-ALPHA-REDUCTASE, ALONE AND IN COMBINATION WITH FINASTERIDE, ON SERUM DIHYDROTESTOSTERONE CONCENTRATIONS IN MEN, The Journal of clinical endocrinology and metabolism, 81(8), 1996, pp. 2942-2947

Authors: GARG DC LASSETER KC SHROTRIYA RC SHAMBLEN EC SHAMBLEN S HOFF JV GALLAGHER SC

Citation: Dc. Garg et al., PHARMACOKINETIC PROFILE OF PILOCARPINE HYDROCHLORIDE IN SUBJECTS WITHIMPAIRED HEPATIC-FUNCTION, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 48-48

Authors: LASKIN OL PATTERSON PM SHINGO S LASSETER KC SHAMBLEN EC

Citation: Ol. Laskin et al., PHARMACODYNAMICS AND DOSE-RESPONSE RELATIONSHIP OF FAMOTIDINE - A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL, Journal of clinical pharmacology, 33(7), 1993, pp. 636-639

Authors: KEHE CR LASSETER KC MILLER NC WICK KA SHAMBLEN EC EKHOLM BP SANDAHL JH CHANG SF GOLDLUST MB KVAM DC HARRISON LI

Citation: Cr. Kehe et al., COMPARATIVE ABSORPTION OF ATROPINE FROM A METERED-DOSE INHALER AND ANINTRAMUSCULAR INJECTION, Therapeutic drug monitoring, 14(2), 1992, pp. 132-134